{"entity":{"id":"nct07101679","kind":"trial","name":"A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial in pancreatic cancer, run by West China Hospital, now recruiting.","summary":"A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer is a phase 2, interventional study registered as NCT07101679 by West China Hospital, with a registry enrolment figure of 23 participants, started 2025-04-16 and due to reach its primary completion in 2027-04-15. Interventions recorded: LICSBR. Conditions listed: Locally Advanced Pancreatic Ductal Adenocarcinoma. Primary outcome: Investigator-assessed Objective Response Rate (ORR). Pancreatic eligibility wording from the registry: \"Inclusion Criteria (1)Histologically confirmed pancreatic ductal adenocarcinoma with diagnosis based on comprehensive assessment of pathology and imaging studies (CT or MRI), supplemented by fibroblast activation protein positron emission tomography-computed tomography (FAPI PET-CT) when necessary, \". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07101679","url":"https://clinicaltrials.gov/study/NCT07101679"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac"],"sections":[],"technologies":["sbrt"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07101679","phase":"2","setting":"A Phase II Clinical Study of GnP Regimen (Nab-paclitaxel + Gemcitabine) Combined With Serplulimab and Stereotactic Body Radiation Therapy (SBRT) as First-line Treatment for Locally Advanced Pancreatic Cancer","sponsor":"West China Hospital","participation":[{"nct":"NCT07101679","source":"https://clinicaltrials.gov/study/NCT07101679","fetchedAt":"2026-10-07T16:55:25.997Z","studySha256":"91abb5b8d9eef03b964feec291c3cd941f1c8059d54e13b9b50e7c2ada73680e","overallStatus":"RECRUITING","lastUpdatePosted":"2025-08-07","leadSponsor":"West China Hospital","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":23,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2025-04-16","startedType":"actual","enrolled":23,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07101679/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"}],"technology":[{"id":"sbrt","kind":"technology","name":"SBRT / SABR (stereotactic radiotherapy)","route":"/technologies/sbrt/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}